Status:
COMPLETED
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Type I-Allergy
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)
Eligibility Criteria
Inclusion
- main symptoms of allergic rhinitis/rhinoconjunctivitis with or without controlled asthma against grass pollen allergens
- positive SPT
- positive EAST
- positive specific provocation test
Exclusion
- serious chronic diseases
- other perennial allergies
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00666341
Start Date
September 1 2007
End Date
May 1 2010
Last Update
November 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prof. Dr. med. Ludger Klimek
Wiesbaden, Baden-W., Germany, 68167